| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 临床阶段(元) | - | 1,766,779,126.83 | 799,447,873.63 | 1,507,098,338.18 | 859,341,319.75 |
| 商业化阶段(元) | - | 2,803,949,393.96 | 1,395,943,785.47 | 5,112,480,745.14 | 3,227,329,697.34 |
| 新兴服务(元) | 756,017,543.57 | 1,226,373,500.56 | 499,946,931.26 | 1,199,333,374.24 | 530,554,265.03 |
| 小分子CDMO解决方案(元) | 2,429,080,191.41 | - | - | - | - |
| 其他(元) | - | - | - | 6,277,840.71 | 4,285,097.32 |
| 营业成本(元) | |||||
| 临床阶段(元) | - | 1,070,280,234.84 | 467,054,341.87 | 893,098,773.91 | 493,840,134.49 |
| 商业化阶段(元) | - | 1,308,953,865.20 | 692,266,703.95 | 2,041,367,918.54 | 1,319,523,355.56 |
| 新兴服务(元) | 530,804,003.34 | 960,670,424.45 | 398,532,323.57 | 881,726,631.79 | 351,535,397.97 |
| 小分子CDMO解决方案(元) | 1,268,260,282.44 | - | - | - | - |
| 其他(元) | - | - | - | 5,606,968.81 | 4,123,945.15 |
| 毛利(元) | |||||
| 临床阶段(元) | - | 696,498,891.99 | 332,393,531.76 | 613,999,564.27 | 365,501,185.26 |
| 商业化阶段(元) | - | 1,494,995,528.76 | 703,677,081.52 | 3,071,112,826.60 | 1,907,806,341.78 |
| 新兴服务(元) | 225,213,540.23 | 265,703,076.11 | 101,414,607.69 | 317,606,742.45 | 179,018,867.06 |
| 小分子CDMO解决方案(元) | 1,160,819,908.97 | - | - | - | - |
| 其他(元) | - | - | - | 670,871.90 | 161,152.17 |
| 毛利率(%) | |||||
| 临床阶段(%) | - | 39.42 | 41.58 | 40.74 | 42.53 |
| 商业化阶段(%) | - | 53.32 | 50.41 | 60.07 | 59.11 |
| 新兴服务(%) | 29.79 | 21.67 | 20.29 | 26.48 | 33.74 |
| 小分子CDMO解决方案(%) | 47.79 | - | - | - | - |
| 其他(%) | - | - | - | 10.69 | 3.76 |
| 收入构成(%) | |||||
| 临床阶段(%) | - | 30.48 | 29.66 | 19.26 | 18.59 |
| 商业化阶段(%) | - | 48.37 | 51.79 | 65.33 | 69.83 |
| 新兴服务(%) | 23.74 | 21.15 | 18.55 | 15.33 | 11.48 |
| 小分子CDMO解决方案(%) | 76.26 | - | - | - | - |
| 其他(%) | - | - | - | 0.08 | 0.09 |
| 毛利构成(%) | |||||
| 临床阶段(%) | - | 28.35 | 29.22 | 15.34 | 14.90 |
| 商业化阶段(%) | - | 60.84 | 61.86 | 76.71 | 77.79 |
| 新兴服务(%) | 16.25 | 10.81 | 8.92 | 7.93 | 7.30 |
| 小分子CDMO解决方案(%) | 83.75 | - | - | - | - |
| 其他(%) | - | - | - | 0.02 | 0.01 |